Stephan Stilgenbauer

Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL

Subgrouping germinal center-derived B-cell lymphomas based on machine learning-deduced DNA methylation modules

NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL

The significance of <scp>PAX5</scp> in Merkel cell carcinoma

A noncoding mutation in the <i>NOTCH1</i> gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—2024 update

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

The NOTCH1 and miR-34a signaling network is affected by <i>TP53</i> alterations in CLL

Comparison of R‐<scp>CHOP</scp>‐14 and R‐mini‐<scp>CHOP</scp> in older adults with diffuse large B‐cell lymphoma—A retrospective multicenter cohort study

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome

Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis

Acquired <i>BTK</i> mutations associated with resistance to noncovalent BTK inhibitors

Nucleosome repositioning in chronic lymphocytic leukemia

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial

Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia

Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform

CONSOLIDATIVE HCT‐ASCT IS SUPERIOR TO NON‐MYELOABLATIVE CHEMO‐IMMUNOTHERAPY IN NEWLY‐DIAGNOSED PCNSL ‐ UPDATED RESULTS OF THE RANDOMIZED PHASE III MATRIX/IELSG43 TRIAL

Richter transformation: epigenetics to blame?

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch &amp; Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Profile of the Multicenter Cohort of the German Cancer Consortium’s Clinical Communication Platform